Sunday September 25, 2022

Regeneron says Covid antibody treatment protects for 8 months

November 09, 2021

Washington: A synthetic antibody treatment developed by Regeneron reduced the risk of developing symptomatic Covid by more than 80 percent up to eight months after receiving the treatment, the US biotech firm said Monday.

The results are "particularly important to those who do not respond to Covid-19 vaccines including people who are immunocompromised," said Myron Cohen, a University of North Carolina at Chapel Hill scientist who is leading a government-sponsored study into the treatment.